BioMarin Pharmaceutical Inc

13. Nov. 2026, 21:07 UTC

Morgan Stanley analyst Sean Laaman reaffirmed an Overweight rating on BioMarin while lowering the price target to $103.00 from $119.00.

12. Nov. 2026, 21:01 UTC

BioMarin Pharmaceutical Inc. shares fell, breaking a recent trend of higher daily closes, contrasting with prior sessions' upward momentum.

11. Nov. 2026, 21:06 UTC

BioMarin Pharmaceutical Inc. shares are up significantly today, trading well above their 20-day moving average and near the upper end of their one-month range.

10. Nov. 2026, 20:16 UTC

BioMarin Pharmaceutical Inc. shares are lower, reflecting a slight decline from earlier gains while remaining above the 20-day moving average.

9. Nov. 2026, 22:01 UTC

BioMarin Pharmaceutical Inc. is trading higher in after-market hours, reflecting notable strength and unusual activity since Monday's close.

6. Nov. 2026, 20:51 UTC

BioMarin Pharmaceutical Inc. shares fell modestly, remaining near the lower end of their one-month trading range amid typical market fluctuations.

5. Nov. 2026, 20:16 UTC

BioMarin Pharmaceutical Inc. shares fell sharply, reversing earlier gains and currently positioned around the midpoint of its one-month trading range.

4. Nov. 2026, 21:02 UTC

JPMorgan analyst Jessica Fye lowers BioMarin Pharmaceutical's price target while maintaining an Overweight rating; company to participate in upcoming investor conferences.

3. Nov. 2026, 21:02 UTC

BioMarin Pharmaceutical Inc. shares are declining after analysts reduced price targets, with Oppenheimer lowering its target to $94 and Morgan Stanley to $119.

2. Nov. 2026, 23:02 UTC

BioMarin Pharmaceutical Inc. reported a net loss of $123 million for Q3 2026, widening from a $31 million loss last year, and lowered full-year non-GAAP EPS guidance.

30. Okt. 2026, 20:08 UTC

BioMarin Pharmaceutical Inc. shares are trading higher after entering a $475 million licensing agreement with GC Biopharma for a potential Fabry disease treatment.

29. Okt. 2026, 22:06 UTC

BioMarin Pharmaceutical Inc. is trading modestly higher in after-market hours, continuing its upward trend after finishing higher for three consecutive sessions.

28. Okt. 2026, 23:16 UTC

BioMarin Pharmaceutical Inc. is trading roughly flat in after-hours activity, remaining near the lower end of its one-month range following a slight decline since Wednesday's close.

27. Okt. 2026, 23:41 UTC

BioMarin Pharmaceutical Inc. is trading higher in after-market hours, recovering from earlier lows and nearing the lower end of its one-month range.

26. Okt. 2026, 20:01 UTC

BioMarin Pharmaceutical Inc sees modest declines today, with options data showing strong call activity ahead of its earnings release on November 2, 2026.

23. Okt. 2026, 20:07 UTC

BioMarin Pharmaceutical Inc shares fell as broader market declines were driven by weak economic indicators and rising oil prices, despite an earlier session rebound.

22. Okt. 2026, 21:01 UTC

BioMarin Pharmaceutical Inc shares are trading modestly lower in after-market hours, remaining near the lower end of their one-month range.

21. Okt. 2026, 19:52 UTC

Morgan Stanley analyst Sean Laaman lowered BioMarin Pharmaceutical's price target to $122.00 from $124.00 while maintaining an Overweight rating.

20. Okt. 2026, 20:01 UTC

JPMorgan raises BioMarin Pharmaceutical's price target to $87.00 while maintaining an Overweight rating, as shares advance amid a rise in the Biotechnology sub-sector.

19. Okt. 2026, 20:07 UTC

BioMarin Pharmaceutical Inc's shares are roughly flat, fluctuating throughout the day and currently positioned near the lower end of their one-month trading range.

16. Okt. 2026, 21:01 UTC

BioMarin Pharmaceutical Inc is advancing in after-market trading, reaching its highest level of the day following Friday's close.

15. Okt. 2026, 20:01 UTC

BioMarin Pharmaceutical Inc. is trading higher, benefiting from significant gains in the Biotechnology sub-sector, despite earlier pulling back from a session high.

14. Okt. 2026, 19:23 UTC

Barclays maintains Overweight rating on BioMarin and raises price target to $114, contributing to the stock's advance amid a broader Biotechnology sector rally.

13. Okt. 2026, 20:01 UTC

BioMarin Pharmaceutical Inc shares fell sharply, continuing a significant decline since Monday's close, remaining well below their 20-day moving average.

12. Okt. 2026, 20:06 UTC

BioMarin Pharmaceutical Inc received upgrades from Raymond James and RAJA to Strong Buy with a price target of $109, as shares advance.

9. Okt. 2026, 20:06 UTC

BioMarin Pharmaceutical will present new data from 13 studies at the American Society for Bone and Mineral Research 2026 Annual Meeting, including findings on voxzogo.

8. Okt. 2026, 20:07 UTC

BioMarin Pharmaceutical Inc shares are modestly lower, tracking broader market declines, as concerns about profitability persist following recent clinical data presentations.

7. Okt. 2026, 20:00 UTC

BioMarin Pharmaceutical Inc shares fell sharply, retracing from an earlier session high, and remain below their 20-day moving average amid a cumulative decline since Tuesday.

6. Okt. 2026, 20:00 UTC

BioMarin Pharmaceutical Inc shares fell sharply, reflecting unusual weakness and trading well below its 20-day moving average amid broader market conditions.

5. Okt. 2026, 20:06 UTC

BioMarin Pharmaceutical Inc is advancing during Monday's session, maintaining gains since Friday, despite pulling back slightly from a mid-session peak.